Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD 0.0790
+0.0020 (2.60%)
Oct 22, 2026, 1:48 PM AEDT
Neurizon Therapeutics Company Description
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia.
Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.
Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Neurizon Therapeutics Limited
| Country | Australia |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Chris-Carol Bremer |
Contact Details
Address: 385 Bourke Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9692 7222 |
| Website | neurizon.com |
Stock Details
| Ticker Symbol | NUZ |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000357261 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Chris-Carol Bremer M.B.A., M.D., Ph.D. | Chief Executive Officer |
| Dan O'Connell | Chief Financial Officer |
| John Clark | Chief Operating Officer |
| Dr. Gary Pitt | Head of Chemistry |
| Dr. James Rixson | Head of Production |
| Dr. Herbert Brinkman | Head of Manufacturing |
| Lidija Damjanovic | Head of Market Engagement and Corporate Affairs |
| Dr. Chris Freitag M.D. | Chief Medical Advisor |
| Dr. Martin Engel | Head of Scientific and Commercial Partnerships |
| Linda McBride R.Ph. RAC | Head of Regulatory |